Widening the options for recurrent malaria

Affiliations

¹ Barcelona Institute for Global Health, ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona 08036, Spain; Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique; ICREA, Pg Lluís Companys 23, Barcelona, Spain; Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain. Electronic address: quique.bassat@isglobal.org.
² Centre for Diagnostics and Antimicrobial Resistance, Institute for Infection & Immunity, St George's University of London, London, UK; Institut für Tropenmedizin Universitätsklinikum Tübingen, Tübingen, Germany; Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon; St George's University Hospitals NHS Foundation Trust, London, UK.

Free article

Comment

Quique Bassat et al. Lancet. 2018.

Free article

. 2018 Apr 7;391(10128):1336-1338.

doi: 10.1016/S0140-6736(18)30630-5. Epub 2018 Mar 29.

¹ Barcelona Institute for Global Health, ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona 08036, Spain; Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique; ICREA, Pg Lluís Companys 23, Barcelona, Spain; Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain. Electronic address: quique.bassat@isglobal.org.
² Centre for Diagnostics and Antimicrobial Resistance, Institute for Infection & Immunity, St George's University of London, London, UK; Institut für Tropenmedizin Universitätsklinikum Tübingen, Tübingen, Germany; Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon; St George's University Hospitals NHS Foundation Trust, London, UK.

No abstract available

Comment on

Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). Lancet. 2018 Apr 7;391(10128):1378-1390. doi: 10.1016/S0140-6736(18)30291-5. Epub 2018 Mar 29. Lancet. 2018. PMID: 29606364 Free PMC article. Clinical Trial.